Biomark Diagnostics Inc. (BMKDF)
| Market Cap | 10.30M |
| Revenue (ttm) | 116.96K |
| Net Income (ttm) | -1.46M |
| Shares Out | n/a |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.134 |
| Previous Close | 0.134 |
| Day's Range | 0.134 - 0.134 |
| 52-Week Range | 0.125 - 0.230 |
| Beta | -0.54 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 26, 2025 |
About Biomark Diagnostics
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts. The company was incorporated in 2014 and is headquartered in Richmond, Canada. [Read more]
Financial Performance
In 2023, Biomark Diagnostics's revenue was 163,220, an increase of 6.34% compared to the previous year's 153,492. Losses were -1.43 million, -22.52% less than in 2022.
Financial numbers in CAD Financial StatementsNews
BioMark's Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction
BioMark Expands Its Liquid Biopsy Platform Receptor Status for Breast Cancer Vancouver, British Columbia--(Newsfile Corp. - December 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pin...
BioMark Expands Its Liquid Biopsy Platform with Two Groundbreaking Publications in Breast Cancer Detection
BioMark Strengthens Liquid Biopsy Platform for Breast Cancer Detection Vancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF...
BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN
BioMark's Liquid Biopsy Technology Offers Promise for NEN Diagnosis Vancouver, British Columbia--(Newsfile Corp. - September 24, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF...
BioMark Diagnostics Completes Testing of over 5,400 Subjects as Part of a Validation Study for Early Lung Cancer Detection
Largest Clinical Study Validating a Metabolite-based Assay for Lung Cancer Screening Vancouver, British Columbia--(Newsfile Corp. - September 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B)...
Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright's 26th Annual Global Investment Conference in New York
Vancouver, British Columbia--(Newsfile Corp. - August 26, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF), a leading developer of liquid biopsy tests for early cancer detectio...
The U.S. Patent and Trademark Office Grants BioMark Patent That Expands Its Claims Covering Its Legacy Liquid Biopsy Assay
The new patent granted by the USPTO strengthens and expands BioMark's global IP portfolio in liquid biopsy, enhancing cancer management solutions. Vancouver, British Columbia--(Newsfile Corp. - July 3...
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research at 2024 GPEN Conference
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy test...
BioMark Announces Warrant Extension and Granting of Options
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company ...
BioMark to Advance Development of Cancer Treatment for Glioblastoma
The Company secured collaborative research funding from Research Manitoba and Mitacs for an animal proof-of-concept study. Vancouver, British Columbia--(Newsfile Corp. - April 9, 2024) - BioMark Diagn...
BioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy compa...
Theresa Peterson Joins Biomark's Advisory Team
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced-stage liquid biopsy company with a focus on...
BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - December 29, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy compa...
BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") a clinical and diagnostic laboratory de...
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy compan...
BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives
Dr. W. Randolph Ford, Ph.D., will be joining BioMark's Advisory team to support Artificial Intelligence and Machine Learning capabilities.
BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test
Vancouver, British Columbia and Quebec City, Quebec--(Newsfile Corp. - November 7, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") a leading liquid biopsy company ...
BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium
Analyses from a retrospective study of early breast cancer metabolomics panel further demonstrate the diagnostic power of BioMark's liquid biopsy platform beyond early lung cancer detection. Vancouver...
BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on ...
Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay
New family of patent granted by Japanese Patent Office enhances BioMark's global intellectual property position in lung cancer detection using urine as a convenient biological sample medium. Vancouver...
BioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - July 25, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on har...
BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting
BioMark's blood-based metabolomic biomarker panel clinically improved early-stage lung cancer detection through stage shifting. Vancouver, British Columbia--(Newsfile Corp. - June 5, 2023) - BioMark D...
BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay
The new family of patent granted by USPTO strengthens BioMark's global intellectual property position in liquid biopsy and early cancer detection Vancouver, British Columbia--(Newsfile Corp. - May 31,...
BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
New analyses from a large retrospective validation study of early lung cancer metabolomics panel, underscoring strength of BioMark's liquid biopsy platform, to be presented. Vancouver, British Columbi...
BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on ha...
BioMark Provides Third Quarter Operational Update and 2023 Outlook
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company wi...